Cancer Research Institute
The Cancer Research Institute (CRI) is dedicated to transforming cancer patient care through pioneering research in immunotherapy. With a mission to turn immunotherapy research into real-world impact, CRI supports scientists, researchers, and clinical trials to develop effective cancer treatments. It fosters strategic partnerships, funds innovative research, and educates the public and medical community about the power of immunotherapy. CRI has a rich history of scientific breakthroughs, including the discovery of immune system mechanisms and the development of immunotherapies that have saved countless lives. It also advocates for equitable cancer care worldwide and promotes collaboration across the global scientific community. CRI's work encompasses funding the full spectrum of discovery from lab to clinic, supporting clinical trials, and accelerating the development of new therapies. The organization emphasizes the potential of immunotherapy to treat all cancers, with over 60 immunotherapies approved by the FDA as of March 2022, covering nearly every major cancer type. CRI's efforts have resulted in 30 cancers now treatable with immunotherapy, and over 120 clinical trials funded, with a total investment of over $560 million. The institute also provides extensive educational resources, hosts conferences, and supports community fundraising to advance cancer immunotherapy worldwide.
Industries
Nr. of Employees
small (1-50)
Cancer Research Institute
Cancer Research Institute, 1234 Cancer Way, New York, NY 10001
Patents
Products
Interactive tumor–immune analytics platform
Open-access web-based analytics and visualization platform integrating large tumor cohort immune and genomic datasets to support exploratory analysis and benchmarking of user datasets against public cohorts.
Curated tumor antigen peptide database
Repository of validated tumor antigen peptides with supporting literature and validation status for use in translational research and clinical trial target selection.
Immuno‑oncology landscape and pipeline reports
Regularly updated, curated analyses of global immuno-oncology clinical development activity and therapeutic pipeline landscapes to guide research and funding prioritization.
Public educational resources on immunotherapy and side effects
Educational content explaining immunotherapy types, mechanisms, potential side effects, response patterns (including pseudoprogression), and eligibility considerations for patients and caregivers.
Interactive tumor–immune analytics platform
Open-access web-based analytics and visualization platform integrating large tumor cohort immune and genomic datasets to support exploratory analysis and benchmarking of user datasets against public cohorts.
Curated tumor antigen peptide database
Repository of validated tumor antigen peptides with supporting literature and validation status for use in translational research and clinical trial target selection.
Immuno‑oncology landscape and pipeline reports
Regularly updated, curated analyses of global immuno-oncology clinical development activity and therapeutic pipeline landscapes to guide research and funding prioritization.
Public educational resources on immunotherapy and side effects
Educational content explaining immunotherapy types, mechanisms, potential side effects, response patterns (including pseudoprogression), and eligibility considerations for patients and caregivers.
Services
Centralized design, funding coordination, and scientific oversight for early-stage multi-center clinical studies evaluating immunotherapy combinations and mechanism-oriented endpoints.
Grant funding, scientific prioritization, and operational advising for investigator-led single-site and translational studies with emphasis on biomarker integration.
An online service that matches patients to relevant immunotherapy clinical trials and provides navigator support for trial identification and enrollment logistics.
Competitive funding streams to bridge technology development and clinical application, including clinic–laboratory integration grants and awards for technology impact.
Postdoctoral fellowships and short-format bootcamps to train researchers in computational immunology, data analysis, and use of interactive tumor–immune platforms.
Organization of international scientific meetings, patient-oriented summits, and community-focused events (including Spanish-language programming) to disseminate research findings and educate patients and caregivers.
Centralized design, funding coordination, and scientific oversight for early-stage multi-center clinical studies evaluating immunotherapy combinations and mechanism-oriented endpoints.
Grant funding, scientific prioritization, and operational advising for investigator-led single-site and translational studies with emphasis on biomarker integration.
An online service that matches patients to relevant immunotherapy clinical trials and provides navigator support for trial identification and enrollment logistics.
Competitive funding streams to bridge technology development and clinical application, including clinic–laboratory integration grants and awards for technology impact.
Postdoctoral fellowships and short-format bootcamps to train researchers in computational immunology, data analysis, and use of interactive tumor–immune platforms.
Organization of international scientific meetings, patient-oriented summits, and community-focused events (including Spanish-language programming) to disseminate research findings and educate patients and caregivers.
Expertise Areas
- Clinical trial management for immunotherapy
- Translational immuno-oncology research
- Tumor–immune bioinformatics and cohort data integration
- Biomarker discovery and validation
Key Technologies
- Monoclonal antibody therapeutics and antibody–drug conjugates
- Bispecific T-cell engager antibodies
- Adoptive cell therapies (CAR‑T, TIL, engineered NK cells)
- Oncolytic virus therapy
News & Updates
CRI discusses the impact of NIH disruptions on cancer research and the importance of sustained funding.
An educational event explaining the differences between immunotherapy and chemotherapy.
CRI honors Dr. Crystal Mackall for her contributions to cancer immunology.
CRI announces new postdoctoral fellows to advance immunotherapy research.
Celebrating innovative scientists driving the future of immunotherapy.
CRI releases a comprehensive report on the state of cancer immunotherapy.
CRI discusses the impact of NIH disruptions on cancer research and the importance of sustained funding.
An educational event explaining the differences between immunotherapy and chemotherapy.
CRI honors Dr. Crystal Mackall for her contributions to cancer immunology.
CRI announces new postdoctoral fellows to advance immunotherapy research.
Celebrating innovative scientists driving the future of immunotherapy.
CRI releases a comprehensive report on the state of cancer immunotherapy.